Financial reports
10-Q
2023 Q3
Quarterly report
17 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
10 Mar 22
Current reports
8-K
Completion of Acquisition or Disposition of Assets
14 Feb 24
8-K
Entry into a Material Definitive Agreement
22 Dec 23
8-K
Departure of Directors or Certain Officers
4 Dec 23
8-K
Other Events
27 Nov 23
8-K
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
13 Nov 23
8-K
Termination of a Material Definitive Agreement
31 Oct 23
8-K
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
13 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
25 May 23
Registration and prospectus
15-12G
Securities registration termination
26 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
POS AM
Prospectus update (post-effective amendment)
14 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
14 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
14 Feb 24
25-NSE
Exchange delisting
14 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
7 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
7 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
30 Jan 24
Other
EFFECT
Notice of effectiveness
16 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
UPLOAD
Letter from SEC
2 Feb 24
UPLOAD
Letter from SEC
2 Feb 24
CORRESP
Correspondence with SEC
30 Jan 24
UPLOAD
Letter from SEC
22 Jan 24
UPLOAD
Letter from SEC
22 Jan 24
EFFECT
Notice of effectiveness
14 Nov 22
CORRESP
Correspondence with SEC
8 Nov 22
UPLOAD
Letter from SEC
8 Nov 22
Ownership
SC 13D/A
TANG CAPITAL PARTNERS LP
16 Feb 24
4
Kathy Yi
14 Feb 24
4
Steven H Stein
14 Feb 24
4
Change in insider ownership
14 Feb 24
4
DONALD J HAYDEN JR
14 Feb 24
4
CARL L GORDON
14 Feb 24
4
Iain D. Dukes
14 Feb 24
4
Bradford D. Dahms
14 Feb 24
SC 13G/A
Frazier Life Sciences Public Fund, L.P.
13 Feb 24
SC 13D/A
TANG CAPITAL PARTNERS LP
12 Jan 24